# Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

> **NCT01525082** · PHASE2 · COMPLETED · sponsor: **Shaheen Shagufta** · enrollment: 20 (actual)

## Conditions studied

- Gastrinoma
- Glucagonoma
- Insulinoma
- Pancreatic Polypeptide Tumor
- Recurrent Islet Cell Carcinoma
- Recurrent Pancreatic Cancer
- Somatostatinoma
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Temozolomide
- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT01525082
- **Lead sponsor:** Shaheen Shagufta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2018-01
- **Final completion:** 2019-12-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01525082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01525082, "Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01525082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*